- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Proactive CRS Management: The Role of Tocilizumab and Beyond
Amrita Krishnan, MD, discusses how data from ASH 2024 highlight the critical role of intravenous immunoglobulin (IVIG) treatment in preventing infections in patients receiving teclistamab, shares her approach to incorporating IVIG into clinical practice, and outlines additional strategies for reducing infection risk and managing cytokine release syndrome (CRS) in patients on bispecific antibody therapies for multiple myeloma.
EP: 1.Emerging Bispecifics in Multiple Myeloma: Real-World Insights and Treatment Strategies
EP: 2.Navigating Adverse Events in Bispecific Antibody Therapies: Infection Prevention and Management
EP: 3.Proactive CRS Management: The Role of Tocilizumab and Beyond
EP: 4.Expanding Bispecific Therapies to Community Settings: Challenges and Innovations
EP: 5.Leveraging Telehealth and Collaboration for Rural and Community Care Expansion
EP: 6.Streamlining Transitions Between Academic and Community Centers
EP: 7.Optimizing Care Models for Bispecific Antibodies: Strategies for Cost-Effective Delivery
Video content above is prompted by the following:
- Data from ASH 2024 suggest intravenous immunoglobulin (IVIG) can play a critical role in preventing infections in patients receiving teclistamab. How do you incorporate IVIG into your clinical practice, and what considerations guide its use?
- Beyond IVIG, what additional strategies or prophylactic measures have you incorporated into your practice to reduce infection risk in patients on bispecific antibody therapies in multiple myeloma?
- Cytokine release syndrome (CRS) remains a common concern with bispecific antibodies. What strategies do you find most effective for managing CRS?
Early Data Show Promising Outcomes as CAR T-Cell Therapy Expands Beyond Academic Centers
January 12th 2026Abstracts presented at ASH 2025 explore CAR T-cell therapy's effectiveness in newly authorized treatment centers, revealing promising outcomes for multiple myeloma patients and the prospect of expanded access.
Read More
